Dr. Alan L Ho, MD, PhD
Claim this profileMemorial Sloan Kettering Cancer Center
Expert in Thyroid Cancer
Studies Thyroid Disease
16 reported clinical trials
26 drugs studied
Area of expertise
1Thyroid Cancer
Global LeaderStage IV
BRAF positive
HRAS positive
2Thyroid Disease
BRAF positive
Stage IV
RAF positive
Affiliated Hospitals
Clinical Trials Alan L Ho, MD, PhD is currently running
T-DM1 + Chemoradiation
for Salivary Gland Cancer
This trial is testing a special drug called T-DM1 combined with regular cancer treatments in patients with HER2-positive salivary gland cancer. The drug targets cancer cells specifically and delivers chemotherapy directly to them. The goal is to see if this combination is safe and effective in preventing cancer recurrence. T-DM1 has shown effectiveness in treating HER2-positive cancers, including breast and salivary gland cancers, by targeting cancer cells and delivering chemotherapy directly to them.
Recruiting1 award Phase 221 criteria
Darolutamide
for Salivary Gland Cancer
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Leuprolide acetate is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the amount of certain hormones in the body. Giving darolutamide in combination with leuprolide acetate may help to stop the growth of tumor cells that need androgens to grow or shrink them.
Recruiting1 award Phase 2
More about Alan L Ho, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Alan L Ho, MD, PhD has experience with
- Lenvatinib
- Trametinib
- Nivolumab And Ipilimumab
- Avutometinib
- Defactinib
- Pembrolizumab
Breakdown of trials Alan L Ho, MD, PhD has run
Thyroid Cancer
Thyroid Disease
Salivary Gland Cancer
Adenoid Cystic Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alan L Ho, MD, PhD specialize in?
Alan L Ho, MD, PhD focuses on Thyroid Cancer and Thyroid Disease. In particular, much of their work with Thyroid Cancer has involved Stage IV patients, or patients who are BRAF positive.
Is Alan L Ho, MD, PhD currently recruiting for clinical trials?
Yes, Alan L Ho, MD, PhD is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alan L Ho, MD, PhD has studied deeply?
Yes, Alan L Ho, MD, PhD has studied treatments such as Lenvatinib, Trametinib, Nivolumab and Ipilimumab.
What is the best way to schedule an appointment with Alan L Ho, MD, PhD?
Apply for one of the trials that Alan L Ho, MD, PhD is conducting.
What is the office address of Alan L Ho, MD, PhD?
The office of Alan L Ho, MD, PhD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.